INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zynex, Inc. - ZYXI

Core Viewpoint - Zynex, Inc. is under investigation for potential securities fraud and unlawful business practices following a significant revenue shortfall and a major drop in stock price due to payment issues from key payers [1][2]. Financial Performance - Zynex reported a revenue shortfall in Q4 2024 attributed to slower than normal payments from certain payers [2]. - The company disclosed that Tricare, which accounts for approximately 20-25% of its annual revenue, has temporarily suspended payments while reviewing prior claims [2]. - Following this announcement, Zynex's stock price plummeted by $3.59 per share, or 51.3%, closing at $3.41 per share on March 12, 2025 [2]. Legal Context - Pomerantz LLP is investigating claims on behalf of Zynex investors regarding possible securities fraud or other unlawful business practices by the company and its officers/directors [1]. - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [3].